Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has
resulted in an unprecedented number of infected people. The highly contagious nature of …

Importance New data and therapeutic options warrant updated recommendations for the use
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …

Background The widespread use of the integrase strand transfer inhibitor (INSTI)
dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate …

Background: With the introduction of integrase strand transfer inhibitor (INSTI)-based
antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently …

Background Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was
recently approved in the United States for the treatment of human immunodeficiency virus …

Objectives Dolutegravir (DTG), a second‐generation integrase strand transfer inhibitor
(INSTI), is now among the most frequently used antiretroviral agents. However, recent …

The 2017 edition of the IAS–USA drug resistance mutations list updates the figures last
published in November 2015. The mutations listed are those that have been identified by …

ABSTRACT Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of
HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory …